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Tumor-specific delivery of biologics 
by a novel T-cell line HOZOT
Teppei Onishi1, Hiroshi Tazawa1,2, Yuuri Hashimoto1, Makoto Takeuchi3, Takeshi Otani3, 
Shuji Nakamura3, Fuminori Sakurai4, Hiroyuki Mizuguchi4, Hiroyuki Kishimoto1, 
Yuzo Umeda1, Yasuhiro Shirakawa1, Yasuo Urata5, Shunsuke Kagawa1 & Toshiyoshi Fujiwara1
“Cell-in-cell” denotes an invasive phenotype in which one cell actively internalizes in another. The 
novel human T-cell line HOZOT, established from human umbilical cord blood, was shown to penetrate 
a variety of human cancer cells but not normal cells. Oncolytic viruses are emerging as biological 
therapies for human cancers; however, efficient viral delivery is limited by a lack of tumor-specific 
homing and presence of pre-existing or therapy-induced neutralizing antibodies. Here, we report a new, 
intriguing approach using HOZOT cells to transmit biologics such as oncolytic viruses into human cancer 
cells by cell-in-cell invasion. HOZOT cells were successfully loaded via human CD46 antigen with an 
attenuated adenovirus containing the fiber protein of adenovirus serotype 35 (OBP-401/F35), in which 
the telomerase promoter regulates viral replication. OBP-401/F35–loaded HOZOT cells were efficiently 
internalized into human cancer cells and exhibited tumor-specific killing by release of viruses, even in 
the presence of anti-viral neutralizing antibodies. Moreover, intraperitoneal administration of HOZOT 
cells loaded with OBP-401/F35 significantly suppressed peritoneally disseminated tumor growth in 
mice. This unique cell-in-cell property provides a platform for selective delivery of biologics into human 
cancer cells, which has important implications for the treatment of human cancers.
“Cell-in-cell” phenomena, in which a whole cell is found in the cytoplasm of another cell, have been reported for 
decades, although their physiologic significance remains unclear1. The formation of cell-in-cell structures occurs 
following cell-cell contact and commonly results from the engulfment of apoptotic cells by phagocytosis; how-
ever, many other types of cell-in-cell structures have been described, such as the invasion of one cell by another2. 
Immune effector cells and their target cells are known to interact in this fashion. Infiltration of immune cells into 
tumors facilitates direct cell-cell contact and the formation of heterotopic cell-in-cell structures and results in 
entotic or apoptotic death of the internalized immune cells. This process reflects one of the mechanisms tumor 
cells employ to evade antitumor immunosurveillance3. However, it was recently reported that penetration of 
tumor cells by immune cells also represents a special form of immune attack, resulting in target cell death as well 
as self-destruction of the invading immune cells4,5.
HOZOT is a novel multifunctional regulatory T-cell (Treg) line established from human umbilical cord 
blood mononuclear cells by co-cultivation with mouse stromal cells. HOZOT cells are characterized by a unique 
FOXP3/CD4/CD8/CD25-positive phenotype distinct from conventional Tregs, such as FOXP3+ natural Tregs or 
induced Tregs6. HOZOT cells exhibit suppressor/helper/cytotoxic activities, and their cytokine expression pattern 
as determined by mRNA profiling resembles those of Th1 and Th2 T cells, CD8+ cytotoxic T lymphocytes, natural 
killer cells, and Tregs7–9. HOZOT cells exhibit cytotoxic activity against various human cancer cell lines but not 
normal human cells. Furthermore, HOZOT cells can actively penetrate target cancer cells and form cell-in-cell 
structures, which may be one of the mechanisms by which HOZOT cells exert cytotoxicity against cancer cells5. 
This unique cell-in-cell invasive property led us to examine the potential of using HOZOT cells as tumor-tropic 
carriers of biologics such as oncolytic viruses.
Oncolytic viruses that can selectively replicate in and lyse infected tumor cells are an emerging therapeu-
tic modality for treating human cancers10. These vectors are designed to induce virus-mediated lysis of tumor 
cells after selective viral propagation within the tumor cell. We developed an attenuated adenovirus, designated 
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OBP-301 (Telomelysin), that drives the expression of E1 genes under the human telomerase reverse transcriptase 
(hTERT) promoter11, and we confirmed its safety after intratumoral delivery in a phase I clinical trial involving 
various types of solid tumors12. We further modified OBP-301 to express the green fluorescent protein (GFP) gene 
for monitoring viral replication. The resultant adenovirus, designated OBP-401 (TelomeScan), efficiently labeled 
tumor cells with green fluorescence, enabling us to track viral spread in vivo13,14. Preclinical as well as clinical 
studies have demonstrated successful virus spread, including spread to the regional lymphatic areas, and prom-
ising antitumor effects were shown with intratumoral administration of the virus15,16. However, systemic intrave-
nous viral delivery was hampered by the presence of pre-existing or therapy-induced neutralizing antibodies17.
Here, we show that HOZOT cells loaded with an adenovirus serotype 35 fiber–modified attenuated adeno-
virus expressing the GFP gene (OBP-401/F35) are internalized in human cancer cells as a stealth carrier. These 
cells form cell-in-cell structures and efficiently destroy the target cells by releasing cytotoxic viruses. Although a 
variety of cells, including stem and progenitor cells, immune cells, and cancer cells themselves, have been inves-
tigated as delivery vehicles for various oncolytic viruses18–22, the tumor-specific homing and cell-in-cell invasion 
capabilities of HOZOT cells suggest that they are ideal virotherapeutic cellular carriers.
Results
Adenovirus serotype 35 fiber–modified adenovirus is a suitable vector for imparting HOZOT 
cells with cell-in-cell invasive activity. To identify the most suitable adenovirus vector for loading into 
HOZOT cells, we first analyzed the expression levels of several adenovirus receptor proteins, such as Coxsackie 
virus and adenovirus receptor (CAR), integrins α vβ 3 and α vβ 5, and CD46, on the surface of HOZOT cells using 
flow cytometric analysis (Fig. 1a). HOZOT cells showed remarkably high CD46 protein expression and slight 
expression of integrin proteins, but no CAR protein expression was detected, suggesting that HOZOT cells are 
susceptible to infection with adenovirus serotype 35 fiber–modified adenovirus (Ad/F35), which can bind to 
CD46 protein. To assess whether the adenovirus infection efficiency depends on cell surface expression of ade-
novirus receptor protein, we analyzed the efficacy of GFP induction in HOZOT cells infected with various types 
of fiber-modified adenovirus vectors that express the GFP protein (Fig. 1b). Consistent with receptor protein 
expression level, non-replicative Ad/F35-GFP, which binds to CD46, induced GFP expression more efficiently 
in HOZOT cells than either non-replicative RGD peptide fiber-modified adenovirus (Ad/RGD), which binds to 
integrins α vβ 3 and α vβ 5, or conditionally tumor-specific replicative adenovirus (OBP-401), which binds to CAR. 
These results indicate that the F35 fiber–modified adenovirus is the most suitable vector for loading into HOZOT 
cells through binding to CD46.
To investigate whether virus infection affects the cell-in-cell activity of HOZOT cells, SW620 human 
colorectal cancer cells and MKN45 human gastric cancer cells were exposed to virus-loaded HOZOT-Ad/F35 
Figure 1. Cell-in-cell activity of HOZOT cells loaded with non-replicative GFP-expressing adenoviruses by 
adenovirus serotype 35 fiber modification. (a) Flow cytometric analysis of adenovirus-related receptor protein 
(CAR, integrins α Vβ 3 and α Vβ 5, and CD46) in HOZOT cells. (b) Phase-contrast and fluorescence images 
of HOZOT cells infected with mock, OBP-401, RGD peptide fiber–modified Ad/RGD-GFP, or adenovirus 
serotype 35 fiber–modified Ad/F35-GFP. Scale bars: 50 μ m. (c) Time-lapse images of SW620 cells treated 
with virus-loaded HOZOT-Ad/F35-GFP. (d) Images of MKN45 cells, showing penetration by virus-loaded 
HOZOT-Ad/F35-GFP cells. White arrows indicate virus-loaded, GFP-positive HOZOT cells. Scale bar: 20 μ m.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:38060 | DOI: 10.1038/srep38060
cells pre-infected with Ad/F35-GFP (Fig. 1c,d). As shown in Fig. 1c, virus-loaded HOZOT-Ad/F35-GFP cells 
penetrated and formed cell-in-cell structures in SW620 cells as early as 50 min after treatment. Virus-loaded 
HOZOT-Ad/F35-GFP cells also penetrated and formed cell-in-cell structures in MKN45 cells (Fig. 1d). These 
results suggest that virus-loaded HOZOT cells maintain cell-in-cell activity identical to virus-free HOZOT cells.
HOZOT cell–based delivery of OBP-401/F35 induces tumor-specific cell death. To evaluate 
the potential for using HOZOT cells as carriers for oncolytic adenoviruses, we generated a telomerase-specific, 
replication-competent oncolytic adenovirus, OBP-401/F35, in which the fiber was modified to adenovirus sero-
type 35 (Fig. 2a). Adenovirus serotype 35 recognizes human CD46 and, moreover, CD46 expression on the surface 
of malignant tumor cells is up-regulated23,24. Indeed, OBP-401/F35 efficiently reduced the viability of all human 
cancer cells examined (SW620, MKN45, HCT116) that expressed both CAR and CD46 proteins (Suppl. Fig. 1). 
When HOZOT cells were infected with OBP-401/F35, GFP expression was efficiently induced in HOZOT 
cells (Fig. 2b). In contrast, to assess whether OBP-401/F35 replicates in HOZOT cells, we analyzed the expres-
sion of hTERT mRNA and the copy number of adenoviral E1A in HOZOT cells. HOZOT cells showed lower 
hTERT mRNA expression compared to cancer cells and low-level virus replication until 48 hours after infection 
(Suppl. Fig. 2). When red fluorescent protein (RFP)-expressing HCT116 human colon cancer cells (HCT116-RFP 
cells) were treated with OBP-401/F35–loaded HOZOT cells (HOZOT-401/F35 cells), the HOZOT-401/F35 cells 
penetrated and induced GFP expression in HCT116-RFP cells (Fig. 2c,d). These results indicate that virus-loaded 
HOZOT-401/F35 cells have a great potential for use in the delivery of telomerase-specific replicating oncolytic 
adenoviruses into tumor cells.
To assess whether virus-loaded HOZOT-401/F35 cells induce tumor-specific virus-mediated cytopathic 
effects, we compared the in vitro antitumor activity of virus-loaded HOZOT-401/F35 cells and virus-free HOZOT 
cells against several human cancer cell lines (SW620, MKN45, and HCT116) and normal human fibroblasts 
(NHDFs). Virus-free HOZOT cells significantly reduced the viability of all human cancer cells examined in a 
Figure 2. HOZOT cell–based delivery of OBP-401/F35 into human tumor cells. (a) Schematic diagram of 
the OBP-401/F35 structure. OBP-401/F35 is a telomerase-specific, replication-competent, adenovirus serotype 
35 fiber–modified adenovirus serotype 5, in which the hTERT promoter drives the expression of the IRES-
linked E1A and E1B genes and the cytomegalovirus (CMV)promoter drives the expression of the GFP gene 
inserted in the E3 region. (b) Phase-contrast and fluorescence images of HOZOT cells infected with OBP-401/
F35. Scale bar: 100 μ m. (c) Phase-contrast and fluorescence images of HCT116-RFP cells after treatment with 
virus-loaded HOZOT-401/F35 cells. White arrowheads indicate HOZOT cells that penetrated HCT116-RFP 
cells. Scale bars: 20 μ m. (d) Phase-contrast and fluorescence images of HCT116-RFP cells after treatment with 
mock, virus-free HOZOT cells, or virus-loaded HOZOT-401/F35 cells. Scale bars: 200 μ m.
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dose-dependent manner (Suppl. Fig. 3). Compared with virus-free HOZOT cells, virus-loaded HOZOT-401/
F35 cells induced a greater cytopathic effect in all human cancer cell lines examined (Fig. 3). In contrast, both 
virus-free and virus-loaded HOZOT-401/F35 cells showed no cytotoxic effect against NHDFs (Fig. 3 and 
Suppl. Fig. 3). These results suggest that virus-loaded HOZOT-401/F35 cells possess greater cytopathic activity 
than virus-free HOZOT cells as a result of their ability to deliver oncolytic adenoviruses to target cells.
OBP-401/F35 loaded into HOZOT cells overcomes antibody-mediated virus neutralization. 
Carrier cells have shown promise as vehicles for the systemic administration of oncolytic viruses25,26, which is 
often hampered by antibody-mediated virus neutralization. We therefore investigated whether virus-loaded 
HOZOT-401/F35 cells exhibit antitumor effects in the presence of neutralizing antibody. In the absence of 
neutralizing antibody, both virus-loaded HOZOT-401/F35 cells and naked OBP-401/F35 efficiently induced 
GFP expression in SW620 human colon cancer cells (Fig. 4a). In contrast, anti-adenovirus neutralizing anti-
body inhibited the virus-mediated induction of GFP expression by naked OBP-401/F35, but the antibody did 
not inhibit virus-loaded HOZOT-401/F35 cell–mediated induction of GFP expression. Moreover, the neu-
tralizing antibody significantly attenuated the virus-mediated antitumor effect of naked OBP-401/F35 but not 
the cell-mediated antitumor effect of virus-loaded HOZOT-401/F35 cells (Fig. 4b). These results indicate that 
virus-loaded HOZOT-401/F35 cells are highly resistant to antibody-mediated virus neutralization.
Virus-loaded HOZOT-401/F35 cells suppress the formation of tumor spheres through virus 
delivery. To further confirm the therapeutic potential of virus-loaded HOZOT-401/F35 cells, we investigated 
Figure 3. Tumor-specific cytopathic effect of oncolytic adenovirus–loaded HOZOT-401/F35 cells. Human 
gastrointestinal cancer cells, SW620 (a), MKN45 (b), HCT116 (c), and NHDFs (d) were treated with mock, 
virus-free HOZOT cells, or virus-loaded HOZOT-401/F35 cells. Cell viability was calculated relative to that of 
the mock-treated group, which was set at 100%. Cell viability data are expressed as mean values ± SD (n = 5). 
*P < 0.05. N.S., not significant.
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the treatment dynamics of SW620 cell–derived tumor spheres after treatment with virus-loaded HOZOT-401/
F35 cells. Time-lapse imaging spanning 48 hours after treatment showed that virus-loaded HOZOT-401/F35 
cells induced GFP expression on the periphery of the tumor sphere (Fig. 5a and Suppl. Video 1). Moreover, 
time-lapse imaging spanning 5 days after treatment showed that HOZOT-401/F35 cells induced GFP expression 
and subsequent cell death in tumor spheres composed of SW620 cells (Supple. Video 2). In addition, virus-loaded 
HOZOT-401/F35 cells significantly suppressed the size of SW620 tumor spheres, although virus-free HOZOT 
cells did not affect the formation of tumor spheres (Fig. 5b). These results suggest that virus-loaded HOZOT-401/
F35 cells efficiently deliver OBP-401/F35 virus to sphere-forming tumor cells, resulting in the suppression of 
tumor sphere formation.
In vivo inhibition of tumor dissemination by intraperitoneal injection of virus-loaded HOZOT-
401/F35 cells. Peritoneal dissemination of cancer cells is one of the main causes of cancer mortality. For 
preclinical evaluation of the therapeutic potential of virus-loaded HOZOT cells, we investigated whether intra-
peritoneal injection of virus-loaded HOZOT-401/F35 cells prevents peritoneal metastasis of HCT116-RFP 
human colorectal cancer cells in vivo. Virus-loaded HOZOT-401/F35 cells or virus-free HOZOT cells were 
injected intraperitoneally in mice 1 week after injection of HCT116-RFP cells into the peritoneal cavity. At 2 
Figure 4. HOZOT cell–mediated protection of OBP-401/F35 from antibody-mediated virus 
neutralization. (a) Phase-contrast and fluorescence images of SW620 cells treated with mock, OBP-401/F35,  
or virus-loaded HOZOT-401/F35 cells in the presence or absence of neutralizing antibody. Scale bars: 200 μ m.  
(b) SW620 cells treated with mock, OBP-401/F35, or virus-loaded HOZOT-401/F35 cells. Cell viability was 
calculated relative to that of the mock-treated group, which was set at 100%. Cell viability data are expressed as 
mean values ± SD (n = 5). *P < 0.05. N.S., not significant.
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weeks after treatment, marked peritoneal dissemination was observed in mice treated with mock control 
or virus-free HOZOT cells, whereas peritoneal dissemination was reduced in mice treated with virus-loaded 
HOZOT-401/F35 cells (Fig. 6a). Quantitative analysis of RFP intensity in the peritoneal cavity revealed that 
virus-loaded HOZOT-401/F35 cells significantly inhibited the peritoneal dissemination of HCT116-RFP cells 
when compared with mock control or virus-free HOZOT cells (Fig. 6b). Histopathologic analysis revealed large 
necrotic areas in tumor tissues treated with virus-loaded HOZOT-401/F35 cells but not in tissues treated with 
mock control or virus-free HOZOT cells (Fig. 6c). The expression of virus-related hexon protein was observed 
in tumors treated with virus-loaded HOZOT-401/F35 cells but not in mock control–treated tumors (Fig. 6d). 
Treatment with virus-loaded HOZOT-401/F35 cells significantly increased the median survival time (MST) of 
HCT116-RFP disseminated tumor–bearing mice when compared to mice treated with mock control or virus-free 
HOZOT cells (46.5 day vs. 38 days; P < 0.05). as determined by the Kaplan-Meier method. In contrast, there was 
no significant difference in the MST between mock control– and virus-free HOZOT cell–treated mice exhibiting 
peritoneal dissemination (38 days vs. 25.5 days). These results suggest that virus-loaded HOZOT-401/F35 cells 
efficiently inhibit peritoneal dissemination of tumors through delivery of oncolytic adenoviruses.
Discussion
The formation of cell-in-cell structures is a biological process following cell-cell contact in inflammatory and 
tumor tissues1,2. Although the biological properties of cell-in-cell structures remain unclear, the cell-in-cell activ-
ity by which immune cells penetrate the cytoplasm of tumor cells has been shown to result in programmed 
cell-in-cell death4,5. HOZOT cells are a novel cord blood–derived line of Tregs that exhibit multiple properties, 
such as cytotoxic activity and cell-in-cell activity against human tumor cells5. These findings have led to consider-
able recent research exploring the therapeutic effects of combining HOZOT cells and oncolytic viruses. Here, we 
investigated the potential of using HOZOT cells as carriers for efficient transmission of the oncolytic adenovirus 
OBP-401/F35 into human cancer cells. Virus-loaded HOZOT-401/F35 cells significantly reduced the viability 
of human cancer cells, but not that of normal cells, through virus delivery. In the presence of anti-adenovirus 
neutralizing antibody, virus-loaded HOZOT-401/F35 cells, but not naked OBP-401/F35 virus, efficiently reduced 
the viability of human cancer cells. Moreover, both in vitro sphere formation and in vivo peritoneal dissemination 
of tumor cells were significantly suppressed in mice treated with virus-loaded HOZOT-401/F35 cells, resulting 
in a significant increase in the survival rate of tumor-bearing mice. Thus, this unique tumor-specific cell-in-cell 
Figure 5. Suppression of SW620 tumor sphere formation by treatment with virus-loaded HOZOT-401/
F35 cells. (a) Time-lapse images of tumor spheres treated with virus-loaded HOZOT-401/F35 cells. (b) Phase-
contrast and fluorescence images of tumor spheres from SW620 cells after treatment with mock, virus-free 
HOZOT cells, or virus-loaded HOZOT-401/F35 cells (left). Scale bars: 500 μ m. Tumor size (diameter) was 
calculated for each group of tumor spheres treated with mock (n = 29), virus-free HOZOT cells (n = 30), or 
virus-loaded HOZOT-401/F35 cells (n = 18) (right). Data are expressed as mean values ± SD. *P < 0.05. N.S., 
not significant.
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property of HOZOT cells confirms their potential for use as a delivery system to target disseminated metastatic 
tumor cells in oncolytic virotherapy.
Carrier cell–based delivery of oncolytic viruses has the advantage of direct virus delivery into disseminated 
metastatic tumor cells by systemic administration25,26. Normal mesenchymal and neural stem cells have been 
investigated as carrier cells for oncolytic viruses because of their tumor tropism induced by tumor-derived 
chemoattractants26. However, stem cell–based delivery systems lack the cell-in-cell invasion property, and the 
tumor-homing ability of stem cells would be limited to the stromal areas surrounding tumor cells. Although a 
variety of immune cells, including cytokine-induced killer cells, dendritic cells, and myeloid-derived suppressor 
cells, can take up viruses, no mechanism to then transmit the viruses to tumor cells has been elucidated20,27,28. 
In the present study, we examined the novel HOZOT line of human T cells, which exhibit cell-in-cell invasion 
and subsequent cytotoxic effects against tumor cells. Virus-loaded HOZOT-Ad/F35-GFP cells and HOZOT-401/
F35 cells maintained the cell-in-cell activity in target tumor cells. Virus-loaded HOZOT-401/F35 cells showed a 
greater antitumor effect than virus-free HOZOT cells, suggesting that the antitumor effect is virus mediated. In 
addition, virus-loaded HOZOT-401/F35 cells exhibited no cytotoxic effect against normal fibroblasts or virus-free 
HOZOT cells. Therefore, due to their cell-in-cell activity, HOZOT cells are ideal carriers for direct, tumor-specific 
intracellular delivery of oncolytic adenoviruses to induce the death of cancer cells.
The presence of pre-existing neutralizing antibodies is a major obstacle to oncolytic adenovirus–mediated anti-
tumor therapies, as most cancer patients have been previously exposed to adenoviruses. Although in a previous 
study we confirmed the regional spread of intratumorally injected adenovirus vectors to the lymphatic vessels29, 
systemic delivery of oncolytic adenoviruses is hampered by the circulation of anti-adenovirus neutralizing anti-
bodies in the plasma30. In the current study, we demonstrated that the penetration of virus-loaded HOZOT-401/
F35 cells into tumor cells circumvents antibody-mediated virus neutralization, whereas infection with naked 
OBP-401/F35 virus is significantly attenuated by neutralizing antibody. We previously showed that transgene 
expression induced by repeated intratumoral injection of a replication-deficient adenovirus vector can be 
detected in tumor tissues throughout the treatment period, despite the presence of neutralizing anti-adenovirus 
antibodies29. Therefore, once virus-loaded HOZOT-401/F35 cells have trafficked to the tumor site, a plentiful 
supply of viruses would be available due to lysis of targeted tumor cells, thus providing a prolonged antitumor 
Figure 6. Suppression of the growth of peritoneally disseminated tumors derived from HCT116-RFP 
cells by treatment with virus-loaded HOZOT-401/F35 cells. (a) Macroscopic appearance and fluorescence 
images of the abdominal cavity at 14 days after treatment with mock, virus-free HOZOT cells, and virus-loaded 
HOZOT-401/F35 cells. Scale bars: 5 mm. (b) Relative fluorescence intensity of peritoneally disseminated 
tumors in mice treated with mock, virus-free HOZOT cells, and virus-loaded HOZOT-401/F35 cells. Data 
are expressed as mean values ± SD (n = 10). Statistical significance was determined using the Student’s t test. 
*P < 0.05. N.S., not significant. (c) Histopathologic examination of excised tumors stained with hematoxylin 
and eosin. Large necrotic area is shown with yellow arrowheads. Scale bars: 100 μ m. (d) Immunohistologic 
analysis of adenoviral hexon protein in mock-treated and virus-loaded HOZOT-401/F35–treated tumor tissues. 
Positive staining is reddish brown (yellow arrowheads). Scale bars: 100 μ m.
www.nature.com/scientificreports/
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effect. Our data indicate that HOZOT cells are ideal stealth-type carrier cells for systemic delivery of oncolytic 
adenoviruses due to their cell-in-cell activity.
Peritoneal dissemination is one of the most frequent causes of mortality in cancer patients31. Although 
multimodal approaches such as intraperitoneal chemotherapy and hyperthermic intraperitoneal chemoperfu-
sion (HIPEC) have been explored32, there is no standard treatment to effectively prevent peritoneal dissemi-
nation. We recently reported that intraperitoneal administration of OBP-301 in combination with cisplatin 
efficiently suppresses the peritoneal dissemination of ovarian cancer cells in vivo33. Intraperitoneal adminis-
tration of OBP-401 is also useful for in vivo identification of peritoneally disseminated human cancer cells in 
fluorescence-guided surgery34. However, local immunologic responses involving peritoneal macrophages, in 
addition to antibody-mediated virus neutralization, may hamper the antitumor effects of this strategy. In the 
current study, however, virus-loaded HOZOT-401/F35 cells significantly suppressed the in vitro formation of 
tumor spheres that mimic disseminated tumor nodules. Moreover, intraperitoneal administration of virus-loaded 
HOZOT-401/F35 cells significantly inhibited the in vivo growth of peritoneally disseminated tumor cells and pro-
longed the survival of tumor-bearing mice. Although allogeneic HOZOT cells may induce the immune response 
in cancer patients, autologous HOZOT cells from cancer patients may be available in the future because our col-
laborators have recently established HOZOT-like cells, which show the similar cell-in-cell activity, from periph-
eral T lymphoid cells (personal communication). Thus, virus-loaded HOZOT-401/F35 cells represent a more 
promising antitumor reagent than naked oncolytic adenoviruses for the treatment of peritoneal dissemination 
in cancer patients.
Recent successes in the development of cancer immunotherapies have underscored the high capacity of the 
immune system to eradicate tumors, generating renewed enthusiasm for identifying methods to enhance antitu-
mor immune responses in cancer patients. Many researchers are looking for attractive candidate drugs that can 
be combined with immunotherapy agents to activate host immunity35. We previously reported that oncolysis 
induced by telomerase-specific oncolytic adenovirus infection might be the most effective stimulus for immature 
dendritic cells to induce specific activity against human cancer cells (i.e., immunogenic cancer cell death)36,37. 
As HOZOT cells are cytotoxic regulatory T cells, virus-loaded HOZOT-401/F35 cells may be effective both as a 
direct cytotoxic agent and an immunostimulatory mediator that induces specific cytotoxic T lymphocytes against 
the remaining antigen-bearing tumor cells. Telomerase-specific oncolytic adenoviruses might also alter the tumor 
microenvironment by stimulating host immune cells to produce endogenous cytokines such as INF-γ 38. Thus, a 
possible strategy for using virus-loaded HOZOT-401/F35 cells includes combination with immunotherapy.
In conclusion, we clearly demonstrated that virus-loaded HOZOT cells possess great potential for 
tumor-specific intracellular delivery of oncolytic adenoviruses through their cell-in-cell invasion activity. The 
ability of virus-loaded HOZOT cells to overcome antibody-mediated virus neutralization and improve virus 
delivery to multiple disseminated tumors makes them promising antitumor agents. The unique cell-in-cell prop-
erty of virus-loaded HOZOT cells provides a platform for selective delivery of biologics into human cancer cells, 
an outcome that has important implications for the treatment of human cancers.
Materials and Methods
Cell lines. SW620 and HCT116 human colorectal cancer cells were obtained from the American Type 
Culture Collection (Manassas, VA, USA). HCT116-RFP human colorectal cancer cells that express RFP were 
purchased from AntiCancer, Inc. (San Diego, CA, USA). MKN45 human gastric cancer cells were obtained from 
the Japanese Collection Research Bioresources (JCRB, Osaka, Japan). NHDF cells were purchased from Kurabo 
(Osaka, Japan). SW620, HCT116-RFP, MKN45, and NHDF cells were maintained in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were routinely 
maintained at 37 °C in a humidified atmosphere containing 5% CO2.
Novel human HOZOT T cells were obtained from Hayashibara Biochemical Laboratories, Inc. (Okayama, 
Japan). HOZOT cells were previously established from human umbilical cord blood6 and characterized as a cyto-
toxic Treg line with cell-in-cell activity5. HOZOT cells were maintained over mouse normal stromal ST2 cells 
(purchased from the RIKEN BioResource Center [Ibaraki, Japan]) and cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. Prior to experiments, 
HOZOT cells were purified by Ficoll-Paque to deplete debris derived from dead mouse stromal cells.
Recombinant adenoviruses and neutralizing antibody. The study utilized the previously con-
structed and characterized telomerase-specific, conditionally replicating, GFP-expressing adenovirus OBP-401 
(TelomeScan), in which the promoter element of the human telomerase reverse transcriptase (hTERT) gene drives 
the expression of the internal ribosome entry site (IRES)-linked E1A and E1B genes. For loading into CAR-negative 
HOZOT cells, the fiber knob of OBP-401 was modified from adenovirus serotype 5 (which binds CAR) to 
adenovirus serotype 35 (which binds CD46) or RGD-peptide fiber (which binds integrins α vβ 3 and α vβ 5). 
The resulting E1A-deletant, non-replicative, GFP-expressing adenoviruses with RGD peptide–modified fibers 
(Ad/RGD-GFP) and adenovirus serotype 35–modified fibers (Ad/F35-GFP) were used to evaluate virus infection 
of HOZOT cells. Recombinant viruses were purified by ultracentrifugation using a cesium chloride step gradient, 
and virus titer was determined by plaque-forming assay using 293 cells. Viruses were stored at − 80 °C. To atten-
uate the effect of recombinant adenovirus, sera containing neutralizing antibody against adenovirus serotype 5 
were purchased from Denka Seiken, Co., Ltd., (Tokyo, Japan).
Flow cytometric analysis. HOZOT cells were labeled with mouse monoclonal anti-CAR (RmcB; Upstate 
Biotechnology, Lake Placid, NY, USA), anti-human integrin α vβ 3 (LM609; Millipore, Temecula, CA, USA), 
anti-human integrin α vβ 5 (P1F6; Millipore), or anti-human CD46 (E4.3; BD Pharmingen, San Diego, CA, USA) 
antibody for 30 minutes at 4 °C. Cells were then incubated with fluorescein isothiocyanate (FITC)-conjugated 
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rabbit anti-mouse IgG secondary antibody (Zymed Laboratories, Inc., South San Francisco, CA, USA) and ana-
lyzed by flow cytometry (FACS Array; BD Biosciences, Franklin Lakes, NJ, USA).
Fluorescent microscopy. HOZOT cells were treated with mock control, OBP-401 (500 multiplicity if infec-
tion [MOI]), Ad/RGD-GFP (500 MOI), Ad/F35-GFP (10 MOI), or OBP-401/F35 (50 MOI). Expression of GFP 
was assessed and photographed using an IX71 fluorescent microscope (Olympus, Tokyo, Japan).
Time-lapse confocal laser microscopy. Virus-loaded HOZOT-401/F35 cells were obtained by infect-
ing HOZOT cells with OBP-401/F35 (5 MOI) for 24 hours and washing twice with fresh medium to remove 
the non-internalized adenovirus. SW620 cells, MKN45 cells, and SW620 tumor spheres were then treated with 
virus-loaded HOZOT/401-F35. The cell-in-cell activity of HOZOT cells within tumor cells was evaluated using 
time-lapse confocal laser microscopy (FV10i; Olympus).
Cell viability assay. Cells were seeded in 96-well plates at a density of 1 × 103 cells/well 24 hours before 
treatment. Cells were then treated with mock control, virus-free HOZOT cells, or virus-loaded HOZOT-401/F35 
cells for 48 hours. Cell viability was determined using a Cell Proliferation Kit II (Roche Molecular Biochemicals, 
Indianapolis, IN, USA).
Sphere formation assay. SW620 cells were seeded in ultra-low-attachment 6-well plates. At 2 weeks 
after seeding, tumor sphere–forming SW620 cells were treated with mock control, virus-free HOZOT cells, or 
virus-loaded HOZOT-401/F35 cells. Tumor sphere size was measured using an IX71 fluorescent microscope.
In vivo peritoneal dissemination model. All animal studies were conducted in accordance with the 
Policy on the Care and Use of the Laboratory Animals, Okayama University. Animal experimental protocols 
were approved by the Ethics Review Committee for Animal Experimentation of Okayama University School 
of Medicine (No. OKU-2011062). HCT116-RFP cells (5 × 106 cells/mouse) were inoculated into the peritoneal 
cavity of 6-week-old female athymic nude mice (CLEA Japan). One week after inoculation, mice were treated 
with mock control, virus-free HOZOT cells (2 × 107 cells/mouse), or virus-loaded HOZOT-401/F35 cells (2 × 107 
cells/mouse). Two weeks after treatment, red fluorescence photographs were taken under a fluorescent micro-
scope from 10 mice in each group, after laparotomy. Tumor volume was calculated based on red fluorescence 
intensity using ImageJ software. The survival rate of mice with HCT116-RFP xenograft tumors was assessed until 
60 days after inoculation.
Histopathologic analysis and immunohistochemistry. Disseminated tumors were harvested from 
mice treated with mock control, virus-free HOZOT cells, or virus-loaded HOZOT-401/F35 cells. Tumors were 
fixed in 10% neutralized formalin and embedded in paraffin blocks. Sections were stained with hematoxylin/
eosin and analyzed under light microscopy. Sections were also prepared for immunohistochemical examina-
tion. After deparaffinization and rehydration, antigen retrieval was performed in 10 mM citrate buffer (pH 6.0). 
Tissue sections were incubated with mouse anti-adenovirus hexon monoclonal antibody (MAB805; Millipore). 
Immunoreactive signals were visualized using 3,3′ -diaminobenzidine tetrahydrochloride solution, and nuclei 
were counterstained with hematoxylin.
Statistical analysis. Data are expressed as means ± standard deviation (SD). A one-way ANOVA followed 
by a Bonferroni multiple-group camparison test was used to compare differences between groups. The log-rank 
test was also used to compare differences in survival rate between groups of mice. Statistical significance was 
defined as a P value less than 0.05.
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